MGST1 and ATG16L1 overexpression, and MGST1 depletion assay were conducted by Medicilon.

Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder, characterized by the presence of β-amyloid (Aβ) peptide plaques, neurofibrillary tangles, and neuroinflammatio

TRIM24 (tripartite motif-containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are epigenetics “readers”and potential therapeutic targets for cancer and other diseases. Y0

Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-select

Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,

Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models

Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li

Poly ADP-ribose polymerases (PARPs) are a family of enzymes related to DNA damage repair process.?Inhibition of PARP1/2 accelerates the damage of injured DNA, which is synthetically lethal to DNA

Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therape

The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.

JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.

美迪西藥代動(dòng)力學(xué)與生物分析部主任章登吉博士將在藥代動(dòng)力學(xué)研究方法與應(yīng)用技術(shù)交流會(huì)上做“高靈敏度Assay在大分子藥代動(dòng)力學(xué)研究中的應(yīng)用”演講報(bào)告，歡迎觀看直播。

美迪西生物部主任毛卓博士做客云講堂，通過(guò)真實(shí)案例深入探討了PROTAC體外實(shí)驗(yàn)在構(gòu)效關(guān)系研究中的應(yīng)用，以及體外assay在推動(dòng)臨床在研PROTAC分子進(jìn)程中的關(guān)鍵作用。

7月14日19：00，美迪西生物部主任毛卓博士將做客云講堂，以《如何選擇合適的體外assay進(jìn)行PROTAC分子構(gòu)效關(guān)系研究》為主題，探究PROTAC的最新研究進(jìn)展、PROTAC技術(shù)當(dāng)前挑戰(zhàn)和未來(lái)趨勢(shì)，通過(guò)真實(shí)案例探討各種PROTAC體外實(shí)驗(yàn)在構(gòu)效關(guān)系研究中的應(yīng)用、體外assay在臨床在研PROTAC分子推進(jìn)過(guò)程中的應(yīng)用等，并分享美迪西PROTAC服務(wù)平臺(tái)是如何助力客戶加速研發(fā)進(jìn)程的，用豐富的團(tuán)隊(duì)實(shí)戰(zhàn)經(jīng)驗(yàn)為您的研發(fā)答疑解惑！

7月14日19：00，美迪西生物部主任毛卓博士將做客云講堂，以《如何選擇合適的體外assay進(jìn)行PROTAC分子構(gòu)效關(guān)系研究》為主題，探究PROTAC的最新研究進(jìn)展、PROTAC技術(shù)當(dāng)前挑戰(zhàn)和未來(lái)趨勢(shì)，通過(guò)真實(shí)案例探討各種PROTAC體外實(shí)驗(yàn)在構(gòu)效關(guān)系研究中的應(yīng)用、體外assay在臨床在研PROTAC分子推進(jìn)過(guò)程中的應(yīng)用等，并分享美迪西PROTAC服務(wù)平臺(tái)是如何助力客戶加速研發(fā)進(jìn)程的，用豐富的團(tuán)隊(duì)實(shí)戰(zhàn)經(jīng)驗(yàn)為您的研發(fā)答疑解惑！

抗體藥物體內(nèi)的多種存在形式使得其PK分析方法學(xué)設(shè)計(jì)較為復(fù)雜，如何考慮待測(cè)分子形式，如何針對(duì)性地設(shè)計(jì)出合適的Assay Format，實(shí)踐中又可能出現(xiàn)什么樣的問(wèn)題和挑戰(zhàn),在本文中美迪西藥代動(dòng)力學(xué)與生物分析部主任章登吉博士將進(jìn)行詳細(xì)闡述。